It all sounds very promising on the surface and CLDX does have a pretty small market cap. But, one still presumably has to be concerned about PFE pulling out of the partnership for the drug. Was that due strictly to changing business priorities at PFE or did it reflect some specific underlying concerns that PFE had with the drug (or some combination of the two)?
CLDX - Looks like results from the ACTIVATE trial have been published. The reuters article is a bit misleading though. The trial did not have an actual control arm and the data cited for the control arm is based on historical data.
Market Data 
Markets 
AI
